virus 9 raav9  (TaKaRa)

Journal: Open Life Sciences

Article Title: CEBPB promotes ulcerative colitis-associated colorectal cancer by stimulating tumor growth and activating the NF-κB/STAT3 signaling pathway

doi: 10.1515/biol-2022-1012

Figure Lengend Snippet: CEBPB affects the progression of UCCRC mice: (a) the modeling method of AOM/DSS-induced UCCRC in mice and treatment regimens, (b) representative photographs of AOM/DSS-induced UCCRC in mice, (c) colorectal length of mice, (d) colon weight of mice, (e) survival rate of mice, and (f) body weight of mice. N = 10, * P < 0.05.

Article Snippet: Recombinant adeno-associated virus serotype 9 (rAAV9) expressing a siRNA targeting CEBPB (siCEBPB), full-length CEBPB cDNA (CEBPB), and scramble control (NC) were generated by Biowit Technologies Co., Ltd. (Shenzhen, China), according to the manufacturer’s protocol.

Techniques:

Journal: Open Life Sciences

Article Title: CEBPB promotes ulcerative colitis-associated colorectal cancer by stimulating tumor growth and activating the NF-κB/STAT3 signaling pathway

doi: 10.1515/biol-2022-1012

Figure Lengend Snippet: CEBPB affects the pathogenic alterations and inflammatory response in UCCRC mice, and representative images of H&E-stained colorectal tissues of mice. The scale bar is 200 μm (a); the concentrations of TNF-α (b), IL-6 (c), and IL-1β (d) in mice’s sera were determined with ELISA kits; the expression of TNF-α (e), IL-6 (f), and IL-1β (g) in colon tissues was determined with RT-qPCR assay, as per the manufacturer’s protocol. * P < 0.05. The red arrows represent the pathological changes.

Article Snippet: Recombinant adeno-associated virus serotype 9 (rAAV9) expressing a siRNA targeting CEBPB (siCEBPB), full-length CEBPB cDNA (CEBPB), and scramble control (NC) were generated by Biowit Technologies Co., Ltd. (Shenzhen, China), according to the manufacturer’s protocol.

Techniques: Staining, Enzyme-linked Immunosorbent Assay, Expressing, Quantitative RT-PCR

Journal: Open Life Sciences

Article Title: CEBPB promotes ulcerative colitis-associated colorectal cancer by stimulating tumor growth and activating the NF-κB/STAT3 signaling pathway

doi: 10.1515/biol-2022-1012

Figure Lengend Snippet: CEBPB alters the expression of the related proteins and the activation of NF-κB/STAT3 signaling pathway, IHC analysis of the protein expression of E-cadherin (a) and Ki67 (b) in the UCCRC tissues of mice. The scale bar is 50 μm and 100 μm. (c)–(g) Western blot analysis of the protein expression of Ki67, E-cadherin, N-cadherin, and vimtein in the UCCRC tissues of mice. RT-qPCR analysis of the mRNA expression of Ki67 (h), E-cadherin (i), N-cadherin (j), and vimentin (k) in UCCRC tissues of mice. (l) Western blot analysis of p-STAT3 and NF-κB-p65 expression UCCRC tissues of mice. (m) Western blot analysis of p-STAT3 expression in SW480 cells treatment with PMA. After PMA or Colivelin TFA treats SW480 cells, clone formation, transwell, and scratch-wound assay were used to detect cell proliferation (n), invasion (o), and migration (p). N = 3, * P < 0.05. PMA, phorbol 12-myristate 13-acetate; the red arrows represent the pathological changes.

Article Snippet: Recombinant adeno-associated virus serotype 9 (rAAV9) expressing a siRNA targeting CEBPB (siCEBPB), full-length CEBPB cDNA (CEBPB), and scramble control (NC) were generated by Biowit Technologies Co., Ltd. (Shenzhen, China), according to the manufacturer’s protocol.

Techniques: Expressing, Activation Assay, Western Blot, Quantitative RT-PCR, Scratch Wound Assay Assay, Migration

Journal: Open Life Sciences

Article Title: CEBPB promotes ulcerative colitis-associated colorectal cancer by stimulating tumor growth and activating the NF-κB/STAT3 signaling pathway

doi: 10.1515/biol-2022-1012

Figure Lengend Snippet: CEBPB activates the NF-κB/STAT3 signaling pathway in UCCRC mice: (a) Western blot analysis of the protein expression of NF-κB-p65 and p-STAT3 in the UCCRC tissues of mice. (b) Representative photographs of the different groups in mice and (c) the colon weight of mice, (d) colorectal length of mice, and (e) the survival rate of mice. (f) Representative images of H&E-stained colorectal tissues of mice. The scale bar is 200 μm. (g) The concentrations of TNF-α, IL-6, and IL-1β in mice’s sera were determined with ELISA kits. (h) The expression of TNF-α, IL-6, and IL-1β in colon tissues was determined with RT-qPCR assay, as per the manufacturer’s protocol. * P < 0.05. The red arrows represent the pathological changes.

Article Snippet: Recombinant adeno-associated virus serotype 9 (rAAV9) expressing a siRNA targeting CEBPB (siCEBPB), full-length CEBPB cDNA (CEBPB), and scramble control (NC) were generated by Biowit Technologies Co., Ltd. (Shenzhen, China), according to the manufacturer’s protocol.

Techniques: Western Blot, Expressing, Staining, Enzyme-linked Immunosorbent Assay, Quantitative RT-PCR

Journal: Open Life Sciences

Article Title: CEBPB promotes ulcerative colitis-associated colorectal cancer by stimulating tumor growth and activating the NF-κB/STAT3 signaling pathway

doi: 10.1515/biol-2022-1012

Figure Lengend Snippet: CEBPB regulates the expression of proteins via activating NF-κB/STAT3 signaling pathway, IHC analysis of the protein expression of E-cadherin and Ki67 in the UCCRC tissues of mice. The scale bar is 50 μm. (b) Western blot analysis of the protein expression of Ki67, E-cadherin, N-cadherin, and vimentin in the UCCRC tissues of mice. (c) Real-time RT-qPCR analysis of the mRNA expression of Ki67, E-cadherin, N-cadherin, and vimentin in colon tissues of mice. N = 3, * P < 0.05. The red arrows represent the pathological changes.

Article Snippet: Recombinant adeno-associated virus serotype 9 (rAAV9) expressing a siRNA targeting CEBPB (siCEBPB), full-length CEBPB cDNA (CEBPB), and scramble control (NC) were generated by Biowit Technologies Co., Ltd. (Shenzhen, China), according to the manufacturer’s protocol.

Techniques: Expressing, Western Blot, Quantitative RT-PCR

Journal: Molecular Therapy. Nucleic Acids

Article Title: Development of a rabbit model for adrenoleukodystrophy: A pilot study on gene therapy using rAAV9

doi: 10.1016/j.omtn.2025.102469

Figure Lengend Snippet: Effect of rAAV9-h ABCD1 treatment on mutant rabbits (A) Monitoring VLCFA (C26:0/C22:0 ratio) levels post rAAV9- hABCD 1 gene therapy. Two-way ANOVA followed by Bonferroni’s multiple comparisons test. Values presented as means (SD), ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (B) Expression of hABCD1 in different tissues among different groups determined by qPCR. ∗ p < 0.05, by one-way ANOVA followed by Dunnett’s multiple comparisons test. (C) Blood biochemical levels before and after treatment in the rAAV9-h ABCD1 group compared with the WT group. AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; TP, total protein; CR, creatinine; TG, triacylglycerol; TCHO, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ALT, alanine transaminase; ALB, albumin; LDH, lactate dehydrogenase. (D) Liver and kidney pathologies in rAAV9-h ABCD1 -treated ABCD1 −/− rabbits, untreated ABCD1 −/− mutants, and the WT group. The black arrow indicates the lipid droplet vacuole. Scale bar, 250 μm.

Article Snippet: The recombinant adeno-associated virus serotype 9 (rAAV9) plasmid, graciously provided by Prof. Patrick Aubourg of INSERM, France, served as the foundational element.

Techniques: Mutagenesis, Expressing